Free Trial
NASDAQ:CRSP

CRISPR Therapeutics Q2 2025 Earnings Report

CRISPR Therapeutics logo
$59.09 +3.00 (+5.35%)
As of 02:09 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CRISPR Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$1.54
Beat/Miss
N/A
One Year Ago EPS
N/A

CRISPR Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$6.44 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

CRISPR Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

CRISPR Therapeutics Earnings Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More CRISPR Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CRISPR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CRISPR Therapeutics and other key companies, straight to your email.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics (NASDAQ:CRSP) is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

View CRISPR Therapeutics Profile

More Earnings Resources from MarketBeat